In a recent retrospective histological study, authors found that a less favorable outcome of breast carcinoma patients is strongly associated with HAS1 expression (but not HAS2 and HAS3) as seen with shorter overall survival, higher relapse rate, estrogen receptor negativity and HER2 positivity [2]. The gene discussed is HAS1; the disease is breast carcinoma.